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Abstract 
 
During the past decade, rapid advancements in sequencing technologies have enabled the study 
of human-associated microbiomes at an unprecedented scale. ​Metagenomics, specifically, is 
emerging as a clinical tool to identify the agents of infection, track the spread of diseases, and 
surveil potential pathogens. Yet, despite advances in high-throughput sequencing technologies 
and bioinformatics algorithms, metagenomics still has limitations barring mass clinical 
acceptance and broad implementation. Algorithms currently struggle to balance sensitivity and 
specificity of discovered biomarkers, genomic reference databases are incomplete, and studies 
are frequently not reproducible beyond the original environmental settings. Once these hurdles 
are overcome, clinical metagenomics will be able to inform doctors of the best, targeted 
treatment for their patients and provide early detection of disease. Here we present an overview 
of metagenomics methods with a discussion of computational challenges and limitations. Our 
review covers clinical applications and presents applications for strain identification of 
Mycobacterium tuberculosis​ (TB), identification of infectious agents in cases of encephalitis, 
biomarkers for Inflammatory Bowel Disease, and explores the challenges of sampling the 
microbiome in various tissues. Our review also summarizes 11 of the most recent clinical 
metagenomics studies and discusses their commonalities and unique features.   
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 Introduction 
 
During the past decade, rapid advancements in genomics technologies have enabled the study of 
human-associated microbiomes at an unprecedented scale. Together with ​a significant reduction 
in cost of sequencing technologies and development of advanced gene-editing tools, the potential 
of leveraging human-associated microbiome data for development of novel ​diagnostic and 
therapeutic tools is enormous. Medical applications include, but are not limited to, infection 
detection, surveillance and tracking of outbreaks, antimicrobial resistance prediction and strain 
resolution, and disease prognosis. However, integration of the field of metagenomics with 
clinical medicine has yet to be accomplished (​Figure 1a​). A large body of work has been 
published in the field of metagenomics, while papers addressing clinical applications of 
metagenomics are just starting to appear (​Figure 1b​).  
 
A microbiome is the microscopic ecosystem of a given habitat, which includes both biotic and 
abiotic elements. Microbiota are the communities of microorganisms (bacteria, fungi, protists, 
parasites, viruses) that simultaneously exist and interact within a microbiome​1​. All environments 
on Earth, and even the space station above Earth, include dynamic microbial communities that 
live on, inside, and around host microbiota. Two methodologies for identifying and analyzing the 
microbiome dominate today’s microbiota studies: culture-dependent and culture-independent 
methods. 
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 Figure 1. (a) ​There is a gap between metagenomics research and application of metagenomics 
discoveries to clinical developments. The missing pieces are standardization of methods and 
data, consensus on best tools and practices, and clinical validation.​ (b) ​The cumulative trend of 
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papers published on metagenomics (blue) and clinical metagenomics (orange). Note: the vertical 
axis is log-based to demonstrate cumulation of papers published in PubMed since 2004. 
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 Figure 2. (a) Sample collection. ​The first step of clinical metagenomics is sample collection 
from the patient. Samples take the form of any fluid (e.g., blood, urine), solid (e.g., feces), or 
alternate sampling method (e.g., swabs) taken from the human body. ​(b) Host-DNA depletion 
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or microbial enrichment. ​Samples taken from living hosts may contain an over abundance of 
host DNA that may overshadow reads; often, host DNA can be mostly removed through 
host-DNA depletion although at a financial cost as well as loss of some microbial material. 
Alternatively microbial enrichment will increase the abundance of microbial DNA in the sample. 
Enrichment occurs after dna extraction, where as host DNA depletion occurs before. These steps 
are optional. ​(c)​ ​DNA sequencing. ​The DNA within the samples is extracted and sequenced. 
Five sequencing platforms are Illlumina, ThermoFisher (not shown), BGI (not shown), 
Nanopore, and PacBio. The latter two generate long-reads (<1,000 bp) while the former three 
generate paired-end short-reads (>300bp). Illumina, BGI, and PacBio determine base pairs 
utilizing fluorescently tagged nucleotides and ​taq​ Polymerase. Nanopore determines base pairs 
by passing a single stranded DNA through a nanopore, the unique interruption in the ion current 
through the nanopore differs by the set of nucleotides in the pore, and ThermoFisher also uses 
pH changes as bases are incorporated to sequence. A computer is capable of guessing (with a 
13% error rate) what nucleotides are in the pore. ​(d) Sequencing technology statistics. ​Illumina 
has the lowest single-pass sequencing error rate, but the shortest read length. Illumina determines 
base pairs by clustering clonally-amplified copies and selecting the dominant color. During the 
sequencing process, strands lag behind or pull ahead of the current base, and the signal becomes 
obscured. This affects accuracy at a distance close to 300bp. PacBio, which produces the longest 
read lengths of the three platforms, does not rely on clusters of identical strands remaining in 
step, but can instead sequence a single strand of DNA one time (10% error rate) or multiple 
times (<0.1% error rate from circular consensus, a.k.a. HiFi reads). This single-molecule, 
multiple pass technique gives PacBio the lowest error rate of the three technologies, and the 
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errors are randomly distributed throughout the read. Nanopore has the longest read length and 
the highest error rate. The error rate is due to sequencing read error. When reading bases through 
the pores, there are multiple nucleotides in the channel at one time which can obscure the base 
pair identification, leading to the high error rate. Illumina had the highest throughput followed by 
PacBio and Nanopore. (Illumina statistics based on NovaSeq6000, nanopore based on 
PromethION, PacBio estimated based on  Sequel II) ​(e) Bioinformatics analysis.​ There are 
three types of mapping algorithms used to identify reads and measure organism abundance. The 
first is mapping-based profiling which maps the entire read to the entire reference. The second is 
marker based profiling, which only maps the reads to parts of the genome that are unique to each 
species or strain (red and orange regions) and not to regions that are homologous (green and 
blue). This step reduces the time it takes to map the reads. Finally, k-mer based profiling, which 
breaks up the reads and references into substrings and compares the substrings. (Binning 
methods are not discussed.) ​(f)​ ​Clinical applications. ​After the reads identities and abundances 
have been found, Bioinformatics analysis returns a report that can inform clinical decisions. 
Clinical metagenomics can be used to detect infections, track the progress of outbreaks, predict 
antimicrobial resistance, and inform doctors of the best disease prognosis.  
 
 
Culture-dependent methods (CDMs) refer to any specific method that requires the growth of 
sample microbes in an artificial environment (i.e., culture) in order to identify, quantify, and 
phenotypically characterize microbial organisms. These methods are currently the gold standard 
for the classification of microbes isolated from their host environment, including those from the 
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human body. CDMs are widely applied in clinical and environmental laboratories in order to 
conduct phenotypic discrimination of bacterial colonies, examination of intracellular 
pathogenicity, and susceptibility to antibiotics​2​. The application of Next-Generation Sequencing 
(NGS) technologies, and subsequent sequence analyses that use specialized computational 
methods, to CDMs has allowed for easier and more refined classification of microbes. CDMs are 
capable of generating accurate inventories of microbial taxa that can grow on the selected media 
and have demonstrated utility in clinical diagnosis. 
 
Culture-independent methods (CIMs) include all methods that do not rely on the growth of 
microbes in culture (e.g., targeted amplicon sequencing, metagenomics, etc.). CIMs can deliver a 
complete and unbiased report on the microbes present in a sample​3,4​. Advancements in high 
throughput technologies have led to a wide applicability of CIMs in microbiome research and 
medicine. Such techniques are used to investigate the genetic material of human or 
environmentally-associated microbial samples. Since CIMs do not need to allocate time for 
bacterial growth, identification of strains and organisms can take place in less time and with 
higher accuracy than with CDMs. In addition, CIMs are capable of isolating novel genomes and 
identifying microorganisms that cannot be cultured. 
 
CIMs are currently the microbial-identifying methods that offer the most flexibility and are 
capable of delivering the most comprehensive results. Our review discusses the advantages, 
limitations, and potential clinical applications of one class of CIMs: metagenomics methods. 
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Current Approaches to Metagenomics 
 
The results of metagenomic studies shed light on the biotic composition of the microbiome and 
the function of the microbial organisms’ genes, both of which can inform translational 
developments in the fields of biology, public health, and medicine (​Table 1​). A metagenomics 
study considers the genes and genomes of all microorganisms from a microbiome (i.e., the 
metagenome)​1​. The DNA composing the metagenome is collected directly from a sample of the 
studied host environment (​Figure 2a​), sheared, and sequenced in order to isolate the base pair 
patterns (​Figure 2c​). This process, called shotgun sequencing, produces a number of sequences 
(referred to as ​reads​) that can be assembled into larger contiguous pieces and taxonomically 
characterized (​Figure 2e​). Generating and analyzing results requires the utilization of complex 
computational algorithms. 
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Table 1. ​Clinical applications and obstacles of applying metagenomic NGS (mNGS). Clinical 
applications of metagenomics methods are a few of the specific areas of clinics to which 
metagenomics methods can be applied. Requirement for metagenomics analysis covers the 
features of methods that are needed for metagenomics to be validated within the given clinical 
application. Sequencing technologies list the current NGS technologies that would be needed for 
the given clinical application. Illumina and IonTorrent represent short-read sequencers. PacBio 
and Nanopore represent long-read sequencers. 16S, 18S, and ITS represents amplicon 
sequencing. Amplicon sequencing is not metagenomics, but rather metataxonomy. 
Clinical Application 
Requirement for 
metagenomics analysis 
Sequencing 
Technology Databases 
Infection detection Highly- accurate methods  
Illumina/IonTorrent 
PacBio/Nanopore 
16S/18S/ITS 
Complete 
Surveillance and 
tracking of outbreaks 
Sample collection 
across large number of 
individuals 
Illumina/IonTorrent 
16S/18S/ITS 
Sequencing 
Technology Specific 
Rapid diagnostics Speed (<4h) Nanopore/PacBio Sequencing Technology Specific 
Antimicrobial 
resistance prediction, 
strain resolution 
Low read error rate PacBio/Nanopore Custom 
Disease prognosis Modeling dynamics 
Illumina/IonTorrent 
PacBio/Nanopore 
16S/18S/ITS 
Custom 
 
 
  
12 
Today’s computational algorithms for metagenomic analysis have limitations. Genetic data 
obtained through metagenomics methods contain an increased number of DNA fragments that 
must be aligned against hundreds of thousands of microbial genomes in order to be analytically 
useful. This increased number of DNA fragments — and the large size of the reference database 
— poses unique challenges to existing metagenomic methods and the computational resources 
they depend on. Additional challenges include the lack of comprehensive gene catalogs, biases in 
functional profiling, and lack of standardization in publishing raw data. Difficulty integrating 
meta-omics analysis tools with existing frameworks also limit and challenge the potential use of 
metagenomic methods. 
 
By identifying microbes from diverse sample types and determining their impact on the 
microbiome, metagenomics has substantial potential as a tool for human health and the diagnosis 
and treatment of disease. Human biomedical studies focus on the variety of microbial diversity 
across body compartments (e.g., gut, skin, nasal, oral) as well as niche specialization within 
those compartments​5​ and how these variables influence the bodies reaction to treatments. For 
example, a comparison of gut microbiomes shows that varied communities of microbiota can 
influence an individual’s reactions to drugs and treatments​6,7​. Metagenomic techniques allow for 
the capture of genetic features (e.g., functional elements, protein domains, or variants) of 
microbes present in the sample, which are then compared to other samples across health and 
disease status. As costs continue to decrease and studies begin to elucidate the therapeutic 
potential of microbiome characterizations, there is a strong potential for the integration of these 
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tools in the clinic. The application of metagenomics in clinical metagenomics has yet to be fully 
explored as clinical metagenomics studies have begun to be published only recently (​Figure 1b​). 
 
Our review of the rapidly evolving approaches to metagenomics explains the limitations of 
CDMs and the rise of CIMs, as well as targeted and untargeted sequencing methods. We outline 
the complexities and limitations of computational algorithms that handle output from sequencing 
technologies. Finally, we provide examples of metagenomic methods, which show promise as a 
valuable tool for developing translational discoveries in clinical laboratories.  
 
The rise of culture-independent genomic-based microbiome profiling 
 
CDMs are the gold standard for microbe identification and analysis in pathology research and 
practice. Microbe morphology, growth, and response to environmental variables (e.g., 
antibiotics, gel composition) have been used for almost 300 years to study and identify 
microbes​8​. CDMs create artificial, controlled environments using a nutrient-rich media which 
can be designed to enrich diverse groups of inure organisms or grow microbes with specific or 
unknown requirements. Once cultivated, these organisms can be phenotypically characterized 
using different microbiological and biochemical diagnosis techniques.  
 
The Sanger automated sequencing method​9​ was developed in the mid-1970s and allowed 
researchers, for the first time, to sequence the base pairs in segments of DNA (called ​reads​). 
Once the content of DNA could be analyzed, researchers started viewing the base pair pattern 
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within the DNA as molecular biomarkers for the classification of microorganisms​10​. At the time, 
the Sanger method was an advancement on CDMs and allowed pathologists to more accurately 
identify microbes from culture. 
 
The 16S rRNA gene is the dominant marker in microbial studies and exemplifies the 
revolutionary nature of Sanger sequencing. This region of the genome codes for a segment of the 
small ribosomal subunit, called the Shine-Dalgarno sequence​11​, which is required for the proper 
initiation, elongation, and termination of DNA translation in prokaryotes​12​ (the homologous 
region in eukaryotic cells is the 18S rRNA gene​13​). Since this segment is vitally important for the 
development and survival of the microbe, it contains regions with very low mutation rates, 
making it ideal for use as a molecular classification marker at higher taxonomic levels (e.g. 
kingdom, phylum)​10,14​. The 16S region also contains regions that are hypervariable​15​, meaning 
the regions have high mutation rates. Thus, the 16S region is ideal for use as a molecular 
classification marker at the lower taxonomic levels (e.g., genus, species)​14,16–18​. Indeed, the 
ubiquitous use of this single genetic marker to identify microbes has led to the formation of 
extensive reference databases just for this gene (e.g., Greengenes ​19​, Silva ​20​).   
15 
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Figure 3.​ Overview of Sequencing Technology. ​(a)​ Read length by sequencing technology 
(vertical axis log based).​ (b)​ Error rate by sequencing technology (vertical axis log based). ​(c) 
Throughput by Sequencing Technology (vertical axis log based).​ (d) ​Error Rate (%) versus 
Average Read Length.​ (e)​ Throughput (gigabase pairs per run) versus Average Read Length. 
Illumina HiSeq data estimated based on HiSeq 2500 machine. Sanger data estimated using API 
Sanger 3500. Data for IonTorrent estimated using IonTorrent PGM. Data for Nanopore estimated 
based on MinION. Data for PacBio estimated based on Sequel II machine. Average read length 
and throughput data obtained from ‘Developments in high throughput sequencing’​21​.  
 
 
Despite advancements in sequencing technologies, multiple factors limit the application of 
CDMs to clinical translation efforts. Culturing procedures are slow, labor intensive, and cannot 
be scaled across a large number of samples. Additionally, profiling beyond strains with CDMs 
alone is challenging. Moreover, much of the microbial diversity observed in the microbiome 
have yet to be cultured due to microbiologists being unable to replicate biologically crucial 
aspects of their host environment in the laboratory setting. Microbiologists do not yet know 
enough about the nutrient and environmental requirements of many microbes to predict what is 
necessary for these organisms to grow. Furthermore, applying such techniques to potentially 
life-threatening bacteria poses safety concerns, and CDMs have limited potential to detect 
viruses, which usually cannot be cultured without host cells​22​. These limitations affected the 
applicability of Sanger sequencing during the 1970s because this type of sequencing requires 
high concentrations of pure DNA that are not always available — especially if the target microbe 
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cannot be cultured​23​. For the study of uncultured microbes, reliance on CDMs was a substantial 
hurdle to metagenomics and clinical research. 
 
CIMs first became possible in the late 1980s with Kary Mullis’ development of Polymerase 
Chain Reaction (PCR)​24​. PCR artificially amplifies specific regions of DNA in order to deepen 
coverage of those regions for sequencing, functional analysis of a specific gene, or detection of 
polymorphisms or point mutations​24–26​. Among other applications, PCR is capable of amplifying 
the 16S rRNA gene of microbes, which isolates the mutation-informative region of DNA for 
sequencing. This can be applied to both cultured microbes (to isolate the 16S region for 
sequencing and analysis) or uncultured microbes. The latter reveals the true value of PCR to the 
microbiology field: it allows for the study and identification of microbes that researchers had not 
yet been able to grow in culture, even if the amount of DNA available at the outset was 
incredibly small. PCR also allowed clinics to diagnose infectious pathogens, such as 
Mycobacterium leprae​ (a bacterium causing leprosy)​27–29​, which researchers and pathologists had 
continually failed to grow and classify using CDMs​30​. 
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 Figure 4.​ ​(a)​ Clinical applications and the required features of metagenomics methods. 
Differences in ​(b)​ long read and ​(c)​ short read sequencing completeness given the same cost per 
sample. Long read sequencing obtains reads from few species, but read coverage is high — 
representing almost the complete coverage of the species genome. Short read sequencing obtains 
reads from many species, but reads only represent a small fraction of the genome — representing 
only a small portion of the assembly of the species genome. Read coverage is represented in 
blue. 
 
 
Despite the emergence of PCR, during the 80s and 90s, the study of the entire genetic content of 
all the organisms in the microbiome (called the metagenome) was limited. The cost of using the 
Sanger sequencing method presented a serious challenge. Beyond the expense, reliance on PCR 
to amplify the DNA segments of organisms that are too low in abundance for sequencing poses 
several challenges. Utilizing PCR before sequencing introduces additional mutations which 
19 
decreases the  accuracy of the results​31​. Moreover, PCR requires the presence of an artificially 
constructed primer that binds downstream of the target gene, thus allowing ​taq ​DNA polymerase 
to bind the strand and begin replication​25,32​. Therefore, the base pair pattern that occurs before the 
target sequence (the binding site of the primer) must already be known in order for PCR to 
work​25​. This leads to an increased abundance of DNA that bind well with the primer, which may 
not reflect the associated species actual abundance in the sample. It was not until the 
development of cheaper sequencing technologies (termed Next Generation Sequencing) in the 
2000s that the full metagenome could be studied.  
 
Today, Sanger is far from the only available sequencing method. Sequencing is increasingly 
done using Next Generation Sequencing (NGS) technologies, which provide researchers with a 
dramatically increased throughput (​Figure 3c; Figure 2e​). When compared to prior sequencing 
methods, NGS technologies yield reads at a rate that is orders of magnitude higher per run and at 
a fraction of the cost per base​8,33​ (​Figure3c; Supplementary Note 1​). Today, Illumina leads the 
market in sequencing technologies that use short-reads (<300 bp) and carry the lowest cost per 
Gigabase pair (Gbp) (​Figure 3a; Supplementary Note 1​). Pacific Bioscience (PacBio) and 
Oxford Nanopore Technologies have developed platforms capable of sequencing long-reads 
(>10,000 - 2.2M bp). While these long-read platforms cost more and have a higher error rate 
when compared to Illumina’s short-reads​8​ (​Figure 3b; Figure 3d​), they are still an improvement 
on Sanger with drastically lower costs per Gbp (​Supplementary Note 1​). In terms of throughput, 
long-read technologies have yet to match Illumina (​Figure 3e​). Short-reads are capable of 
covering more microbes than long-reads, however, these reads are capable of covering less area 
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of the genome than long-reads can (​Figure 4b; Figure 4c​). Bacteriophages and viruses have 
genomes sized between a few thousand bases, where long-read sequencing technologies can 
cover the entirety of the genome, to several hundred kilobases. Bacterial genomes are 0.5 Mb to 
10 Mb in length. Eukaryotic genome length varies across and within kingdoms from 
approximately 10 Mb in some fungi to more than 100000 Mb in certain plants​34​. 
 
These advances in NGS technologies have allowed for the creation of metagenomic methods 
(more specifically ‘shotgun metagenomics’), where all the DNA in the sample is sheared, then 
the pieces are sequenced (​Figure 2c​) and analysed using computer software​1,35​ (​Figure 2e​). 
Metagenomic methods are capable of analyzing the entire collection of genomes and genes from 
all microbes present in the microbiome without relying on culture or amplification. The 
important advantage of metagenomic methods is the ability to quantitatively characterize the 
microbial communities in a sample by determining the relative abundance of and revealing 
potential interactions amongst species. Additionally, metagenomics allows for the 
characterization of genomic features (e.g., function) within the sample and allows for 
comparison across multiple samples and sample types. Metagenomic methods can easily detect 
the presence of viruses, fungus, and yet-to-be cultured bacteria. The use of complex 
computational algorithms needed in the analysis of metagenomic methods allow for a complete 
genomic analysis of the entire microbiome. 
 
Although metagenomic methods show great promise in advancing the fields of biology and 
biomedical research, they are not without limitations. Despite the ability of the metagenomic 
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methods to infer the relative abundances of microbes (​Figure 2e​), such methods cannot 
differentiate between living and dead microbes​36​ (although this can be achieved through 
metatranscriptomics, but for typically double the cost) and have limited ability to detect microbes 
that have low DNA representation in a sample. Additionally, the ability to study the microbiome 
from human-dominated samples (e.g., tissue biopsy) is curbed as host DNA tends to overshadow 
microbial reads​3​. Further, clinical applications are complicated by the different metagenomic 
prerequisites (​Table 1; Figure 4a​). Many challenges, however, lie with the computational aspect 
of the methods, which have further variety even in run times processing the same data (​Figure 
5c​). 
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 Figure 5​. Taxonomic Profiler Statistics. ​(a)​ A side by side comparison of sensitivity and 
precision at the genus level. There is no profiling technology with both precision and sensitivity 
both above 0.50. ​(b)​ A side by side comparison of sensitivity and precision at the species level. 
There is no mapping technology with precision and sensitivity both above 0.50.​ (c) ​CPU time, in 
hours, for each profiler to process the CAMI II Mouse Gut sample. 
CPU time data used from OPAL​37​. 
Precision and Sensitivity data used from CAMI​38​. 
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 The computational challenges and limitations of metagenomic methods 
 
NGS technologies are capable of generating today’s “big data” sets across large-scale clinical 
cohorts. Large data sets generated by metagenomics methods require the use of sophisticated 
bioinformatics algorithms that are capable of differentiating technical noise from biological 
signals in the data​39​ and accurately assessing the metagenomic content of a given sample​40​. 
However, several challenges must be addressed in order to leverage the full potential of 
metagenomic computational techniques in the clinical setting, including: lack of standardization 
in bioinformatics techniques, widely varying performance of such algorithms, and the lack of 
comprehensive reference databases (​Figure 1a​).  
 
Developing an effective clinical diagnostic technique capable of properly informing medical 
decision-making requires specification of a standardized, detailed, and replicable procedures​41,42​. 
In contrast, metagenomic computational techniques and pipelines are frequently published and 
distributed without standardized workflows, parameter settings, or input/output formats​38,43​. As a 
result, metagenomic bioinformatics pipelines are frequently updated and evolve as new 
algorithms and tools are published​44​. The ever increasing rate of newly developed computational 
methods and sequencing technologies causes the few existing published standardized procedures 
for metagenomic analysis (such as the admirable efforts of the Human Microbiome Project’s 
“Manual of Procedures” ​45​) to quickly become irrelevant. While some marker gene approaches, 
such as those using 16S rRNA, have begun to be standardized​46​, there is less standardization and 
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consensus for whole genome shotgun (WGS) methods​47​. Only recently have large-scale, 
unbiased assessments of individual WGS metagenomic tools been performed ​38,43,48,49​, with little 
in the way of standardizing entire computational pipelines. The academic software development 
community has made some effort to facilitate the ease of incorporating and assessing the 
performance of new methods in computational pipelines​37,50–52​, but these efforts have not yet 
been widely adopted. This general lack of standardization results in many bioinformatics 
pipelines being created to analyze specific kinds of data resulting from measurements of specific 
biological samples using specific sequencing technology. Such a “bespoke” approach to software 
development limits a potentially wide adoption in the clinical setting where these exact 
conditions may not exist. 
 
Today’s field of metagenomics research is dominated by a wide range of bioinformatics tools 
that have been published with very different performance characteristics. As a rapidly 
developing field, metagenomic bioinformatic tools, especially those in WGS metagenomics, still 
have room for improvement​38,43,48,49​. One example can be found in metagenomic assembly — the 
process of building longer sequences from the shorter reads that are output from a sequencing 
machine, which can then be used for further analysis such as assessing the gene content of a 
metagenome. One study shows that current assemblers struggle to resolve individual strains from 
a metagenomic sample​38,43​, a task important for detecting pathogens. Taxonomic profiling, 
detecting the presence and relative abundance of microbial taxa in a given sample, is another 
common computational technique for which there is little guidance on how to select the best tool. 
The consensus among all large-scale benchmarking studies is that selecting a single “best tool” is 
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often not possible or straightforward​38,43,48,49​. This is due to some tools excelling at different 
specific metrics, including: sensitivity (correctly detecting microbial taxa that are actually 
present in a sample), specificity (correctly reporting as absent taxa that are not present in a 
sample), and correct prediction of the relative abundance of taxa. No current analytic technique 
excels at all three (or even two) of these metrics​38,43​ (​Figure 5a; Figure 5b​). Expert-level 
proficiency is often required in order to select the best possible tool for a given clinical 
application, and many medical institutions now tasked with metagenomics research lack access 
to computational expertise. In addition, metagenomic computational tools struggle with poor 
performance when asked to analyze samples at a resolution finer than the taxonomic level of 
genus​38,43​. This is an unfortunate limitation when information at the level of species or strain is 
required in clinical settings.  
 
Broad application of metagenomic computational techniques are presently limited in the clinical 
setting due to many incomplete, biased reference databases. Lack of comprehensive reference 
databases​3,4,44,53​ are another example of a need for a reference database of information concerning 
microbial organisms. Most metagenomic tools use a reference database comprised of information 
concerning microbial organisms in order to identify material from samples — including whole 
genome sequence databases​54​, databases of gene families​55​, and databases of taxonomic 
relationships​56,57​ (we refer to such information here collectively as “reference databases”). 
Currently available reference databases can be extremely variable in composition, and no single 
database represents the totality of existing information. For example, a recent analysis of fungal 
reference genome databases shows a greater than 30% discrepancy​58​ at the species level between 
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different reference databases. Similar discrepancies have been found in protein orthology 
databases​59​ and in taxonomic databases​60,61​. Furthermore, reference databases continue to 
experience unprecedented growth in size​62,63​. Some computational tools fail to utilize up-to-date 
reference databases due to the time-consuming​64​ or difficult to implement nature of 
post-processing procedures​65​. The use of biased, incomplete, or outdated reference databases can 
further negatively influence metagenomic computational algorithm performance. Expert-level 
proficiency is often required to select for an application the reference database that is most 
appropriate, up-to-date, and correct. The computational skills required to apply and interpret 
metagenomics methods are not included in most graduate-level biological or biomedical 
curricula​66–68​. 
 
Leveraging metagenomics approaches to develop novel diagnostic tools for human disease 
 
There currently exists great potential for using metagenomic methods to develop tools capable of 
detecting microbiota associated with human disease, infectious disease, and foodborne illness. 
The microbiome has been proven to be an effective biomarker for conditions such as colorectal 
cancer​69–71​, inflammatory bowel disease (IBD) ​72,73​, and various metabolic syndromes​74–76​. 
Moreover, metagenomics can potentially be leveraged to produce applications that can be used to 
determine the risk of infection during treatment procedures and can be used to develop 
pre-operative procedures to reduce risk of complications. In some cases, microbiome analysis 
may provide better insights into the etiology of disease then established diagnostic methods (e.g., 
blood sample analysis).  
27 
 Infections within different tissue types pose unique challenges to the successful development of 
metagenomics-based methods to clinical settings. Microbiomes associated with the human body 
are sensitive to changes in diet​77–81​, medications ​82–84​, nutritional supplements​85​, environment​86​, 
and health conditions​87​. Microbiome compositions in the gut, skin, and other tissue types and 
organ systems can therefore be used as a predictor of illness. Colorectal cancer (CRC) -- a 
common cause of mortality across the globe -- has been linked to a noticeably altered microbial 
community within the intestines. Metagenomic analysis of gut microbiome in patients with CRC 
showed a reproducible increase in microbial species richness. Metagenomic analyses exploring 
microbial function and genomic content have established links between gluconeogenesis, 
putrefaction, and fermentation pathways in microbiota with CRC​88​. Longitudinal studies have 
improved detection accuracy based on insights from combining global data from eight distinct 
geographical areas, which found that 29 core species were significantly enriched in the intestines 
of patients with CRC​89​. CRC has also been shown to create an altered viral community within 
the intestines, which could also be detected using metagenomics methods​90​. Furthermore, a 
number of tumor-associated microbiota have been linked to specific oral microbiota, suggesting 
that oral samples may provide an even easier sample site when compared to the gastrointestinal 
tract​91​. 
 
Analysis of the microbiome also shows strong potential for the diagnosis of inflammatory bowel 
disease (IBD), with the capacity to predict patient response to treatment and the chances of 
post-treatment relapse. Analysis of the gut microbiome in patients with IBD and irritable bowel 
28 
syndrome (IBS) show distinct microbial composition in the intestines of individuals who were 
diagnosed with the two conditions​73​. Current diagnostic techniques for IBD and IBS often fail to 
distinguish between the two conditions, since they present similar symptomology in individuals 
suffering from chronic gastrointestinal distress. These studies have also led to the identification 
of key bacterial species with possible links to both IBD and IBS conditions​73​. 
Metagenomic-based approaches may allow physicians to distinguish between IBD and IBS and 
may provide researchers insight into the different causes of these diseases -- potentially leading 
to novel treatments for each. Beyond the diagnostic potential of the microbiota in IBD, 
metagenomics has also provided clinicians and researchers with a roadmap for future 
intervention studies. Using metagenomics to link IBD severity with microbiota structure and 
diet, several studies have already begun tailoring dietary and nutritional interventions for patients 
with IBD​92,93​.  
 
The strategy of linking metagenomics with other metadata and variables, like diet, has strong 
potential beyond gastrointestinal disorders. In addition to diagnosis of a known disease, 
metagenomics provides a unique opportunity to explore diseases of unknown etiology. This can 
be particularly helpful in the face of emerging, zoonotic, or rare infectious agents. Furthermore, 
metagenomics has provided the opportunity to discover previously unknown and unstudied 
classes of viruses, which may have unappreciated roles in disease​94​. Additionally, metagenomics 
allows the opportunity to study the interactions of different microorganisms (bacteria, virus, 
eukaryotic microbes) to produce disease phenotypes. This is, in fact, a paradigm shift from the 
last century of detecting/diagnosing ‘the’ organism causing disease. Metagenomic techniques 
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allow researchers to characterize the entire microbiome and the relative contributions of 
individual components and interaction effects towards disease phenotypes. 
 
This application to phenotypes is not limited to disease, but also phenotypes associated with 
mental health issues. For example, human genome analysis is often used when studying the 
development of schizophrenia​95​, however, in a recent 2018 study utilizing blood samples, 
patients with schizophrenia are shown to have higher microbiome diversity than others with 
amyotrophic lateral sclerosis and bipolar disorder, and healthy controls​96​. The gut microbiome of 
schizophrenia patients, too, differed from gut microbiomes of healthy control groups​97​. There is 
evidence that the gut microbiome is capable of affecting behavior associated with 
schizophrenia​97​ with additional studies suggesting this could occur through the 
microbiota-gut-brain axis (MGB)​98​, though relationships between the MGB and schizophrenia 
are not well studied. The connection between host-associated microbiota and mental health 
extend beyond schizophrenia to phenotypes for anxiety and trauma-related disorders​99​. 
 
Metagenomics-based studies also have potential to revolutionize the way well-understood 
bacterial infections are identified, affecting treatment plans. When treating bacterial infections, 
clinics typically prescribe broad spectrum antibiotics. Clinicians could send a sample of infected 
tissue to a lab for a more specific diagnosis; traditionally, a lab uses culture-based methods to 
identify the infecting agent in order to choose a more specific antibiotic to prescribe. However, 
this process can take multiple days, during which time the broad-spectrum antibiotics can harm 
the natural microbiome of the patient, worsen symptoms, or have no effect on the infection, 
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allowing it to continue spreading in the patient’s body. A culture-independent technique using 
diagnostic PCR, which is used to amplify the DNA of specific microbes known to cause certain 
diseases, can fail to identify the harmful biota. Metagenomic methods can provide results in 
hours (not days), and with the use of amplification techniques of untargeted sequences, a patient 
can get treatment specific to the composition of the infection. These amplification techniques do 
incur biases in the resulting sequences, and caution should be used when utilizing them​100​. 
Ultimately, metagenomics can help a patient avoid the harmful effects of broad-spectrum 
antibiotic treatment and potentially limit the evolution of new antibiotic resistant bacterial 
strains. 
 
Metagenomics can provide more information than simply identification of the cause of diseases 
and infections -- it also has potential for early diagnostic prior to an individual’s manifestation of 
noticeable symptoms. Research in this area is especially important for cancer patients because 
chemotherapy treatments weaken the immune response to foreign pathogens. A massive 
longitudinal study found that a decrease in stool microbial richness is associated with infection 
while receiving induction chemotherapy treatments for leukemia​101​. An additional study found 
that cancer patients receiving Hematopoietic stem cell transplantation are at an increased risk for 
bloodstream infection if the gut microbiome, before chemotherapy, shows decreased diversity 
and lowered abundance of certain taxa​102​. 
 
Metagenomics studies also show promise in the development of strain identification for 
Mycobacterium tuberculosis​ (TB) -- which has an emergent strain showing drug resistance to 
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isoniazid and rifampicin, called MDR-TB. Today’s available treatment plans for additional 
strains, resistant to fluoroquinolones and other antibiotics, called XDR-TB, have only a 19% 
favorable outcome​103​. Current analysis of globally reported cases of TB show 4% of cases being 
rifampicin resistant​104​. Drug resistance for cases of TB were traditionally determined using 
CDMs, whereby the infecting strain is grown in the presence of various antibiotics. A CIM, 
utilizing GeneXpert technology, has been implemented, and it can detect cases of TB on site and 
identify rifampicin resistance within two hours​105​. The results of this test can determine whether 
or not a patient should receive treatment for MDR-TB or the standard TB treatment. Although 
reliable for fully evolved MDR-TB strains, recent genetic analysis of the evolution of TB drug 
resistance have shown that the development of resistance to isoniazid occurs before the 
development of resistance to rifampicin​103​. Patients infected with TB at earlier stages of drug 
resistant evolution, resistant to isoniazid but not rifampicin, would not be identified as MDR-TB 
by the current CIMs. The treatment of these cases with the standard TB treatment allows for the 
further evolution of antibiotic resistance into MDR-TB, thus increasing its prevalence. 
 
Mycobacterium tuberculosis ​is not the only bacterium in need for more precise monitoring 
techniques. Harmful bacteria found in farm animals and meat produced for human consumption 
have developed a resistance to Tigecycline (an antibiotic of last resort to treat severe infections). 
The current cause of this resistance is associated with the evolution of two genes named ​tet​(X3) 
and ​tet​(X4), which inactivate all tetracyclines (the classification of antibiotics under which 
Tigecycline falls). Even newly FDA-approved antibiotics, including eravacycline and 
omadacycline, are also ineffective. These two genes are found on plasmids and can therefore be 
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copied and given to other bacteria through horizontal gene transfer. The spread of resistant 
bacteria and their genes have not been fully quantified; however, resistant strains have already 
been found in hospital patients in China​106​. Metagenomic-based methods have the ability to 
quickly determine the resistance of a bacterial strain before the administration of potentially 
ineffective drugs -- a development key to saving the lives of thousands of individuals affected by 
antibiotic-resistant strains of harmful bacteria. 
 
Encephalitis is an inflammation of the brain caused by an infection that, if left untreated, can 
result in serious disability and carries a 30% mortality rate. Currently, available reference 
databases for encephalitis are incomplete; identification of the bacterial agent is typically 
performed using diagnosis PCR, which only amplifies the DNA of microbes already known to 
cause encephalitis. Currently, the instigating microbe in more than 33% of encephalitis cases are 
unidentified. NGS based methods are capable of identifying the cause of encephalitis, and in the 
process, identify strains and organisms not previously associated with the condition. Therefore, 
metagenomics methods are capable of identifying malicious microbes (even those never 
associated with harmful infections)​107​. 
 
However, there are unique challenges associated with detecting infectious diseases from different 
human tissue types and a potential necessity for enrichment protocols designed to remove host 
DNA. Sources for studying the microbiome within humans come in a variety of forms, each of 
which have their own difficulties during DNA processing prior to sequencing. These sources 
include solids, such as feces; tissues, such as colon, cancer cells, or other organ samples; swabs, 
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such as from sampling the skin, oral, nasal or vaginal epithelial cells; and liquids, such as saliva, 
breast milk, urine, or blood. Samples taken from tissues and swabs tend to be oversaturated with 
the individual’s own human DNA (>90% human genome-aligned reads for swab samples​108​) . 
This oversaturation can obscure the infecting microbe(s) and increase the likelihood of false 
negatives. There are two general ways to remove host DNA from a sample - either depletion of 
host cells or enrichment of microbial cells​109,110​. Although these techniques sound similar, the 
approaches are different. Depletion of human DNA is completed pre-extraction (​Figure 2b​) by a 
selective lysis and degradation of the eukaryotic (e.g., human but also fungal and protist) cells 
followed by purification of the sample to remove the degraded cells. This process leaves the 
intact bacterial cells behind to be extracted. Recent work has been able to remove as much as 
99% of human DNA from lung tissue before the PCR process​111,112​. Alternatively, enrichment of 
microbial cells is completed post-extraction (​Figure 2b​) by a methylation selection, where 
CpG-methylated host DNA is selectively bound and the microbial DNA is eluted​110​. For 
example, there was a 50-fold decrease in reads aligning to host genomes when using this 
method​110​. Both methods have a potential to remove microbes from the sample during this step; 
host depletion will lyse fungal and protist cells and may also lyse bacterial cells, and not all 
microbial cells are methylation free. Therefore, using host depletion techniques prior to 
metagenomic methods may prevent the detection of parasitic protists, such as those that cause 
malaria or giardiasis. Fluids, as well, tend to be oversaturated with human DNA (>90% saliva 
metagenomic reads mapped to human genome​108​) but are also severely diluted due to their 
nature, which results in extremely low yields of microbial DNA within the sample. To 
circumvent this, fluids have been mostly studied by metataxonomic methods (i.e., 16S rRNA 
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amplicon sequencing). However, efforts are being made to adapt metagenomic methods and 
microbial enrichment techniques to study these samples. For example, a microbial enrichment 
method increased the number of mapped reads to the ​Neisseria gonorrhoeae​ genome from 1% 
up to 43% in clinical samples of urine that tested positive for ​N. gonorrhoeae​113​. The most 
common source of starting material for human metagenomic studies is fecal samples, which is 
often used as a proxy for studying the gut microbiome. Unlike other sample sources, fecal 
samples have less host DNA contamination​114​ (<10% metagenomic reads mapped to the human 
genome​108​ ) and depletion of host DNA is not needed. In a recent clinical study which used fecal 
samples to study the longitudinal effect of a fecal transplant in children with ​Clostridioides 
difficile ​did not complete any host depletion and 98.26% of all reads mapped to bacterial 
genomes with 1.66% of all reads mapped to viruses and archaea​115​. 
 
There are other diagnostic applications outside of those mentioned. A review of the current 
clinical metagenomic studies in the last five years showed sample sizes varying from 1 to 204 
with both fresh and frozen samples and sequencing depth as low as .0002 and as high as 9.75 
Gbp per sample. The main sequencing technology being used is Illumina. A variety of 
bioinformatics tools are in use with the most popular being MetaPhlAn2 used in 55% of selected 
clinical metagenomic studies (​Table 2​). 
 
Table 2: An overview of clinical metagenomics studies published between 2015-2019. ​Ref​ is 
the citation for the clinical metagenomics paper. ​Host-DNA depletion​ is yes/no do they process 
the sample to remove host DNA ​before​ sequencing. ​Sequencing technology​ is the sequencing 
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technology used to sequence the sample. Tissue is the source of the sample from the subject. 
Sequencing Depth​ is given in Gbps. This is the throughput of each study, an ‘X’ is given when 
the data is not publicly available for analysis. ​Disease​ is the ailment that the study focuses on. 
Data public​ are the raw reads from the study publically available (yes/no). ​Sample size (n)​ is the 
number of total participants in the study. ​Bioinformatics tools​ are the computer programs used to 
analyse the sequenced data. ​Fresh or frozen samples​ tells whether the samples taken were frozen 
before sequencing or used fresh. 
*Sputum refers to saliva and mucus that is eliminated from the respiratory tract.  
B​BLAST based tool 
I​Data only available on non-SRA site 
Ref 
Host-DNA 
depletion 
Sequencing 
technology 
Sequencing 
depth 
(Gbp) Tissue Disease  
Data 
public 
Sample 
size (n) 
Bioinformatics 
tools 
Fresh or 
frozen 
samples 
116 Yes   Illumina HiSeq 2500 X Bone and joint 
Bone and 
joint 
infections 
No 47 
MetaPhlAn2 
Kraken 
Bowtie2 
Frozen 
117 Yes Illumina MiSeq 2 Aortic valve 
Infective 
endocarditis Yes 1 
CLARK  
MetaPhlAn2 
mothur 
UBLAST 
Frozen 
118 No Illumina MiSeq 0.041 Aortic valve 
Infective 
endocarditis Yes 1 
CLARK 
USEARCH 
MetaPhlAn2 
BWA 
BLAST 
Frozen 
119 No Illumina MiSeq N/A 
Cerebrospinal 
fluid 
Toscana 
virus Yes​
I 1 
TOSV 
SmaltAlign 
VirMet 
Fresh 
120 No Illumina GAIIx 0.07 Sputum* 
Polymicrobi
al infections Yes 1 
SMALT 
BLASTn Frozen 
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121 Yes Illumina NextSeq 9.75 
Feces and 
rectal swabs 
Klebsiella 
pneumoniae  Yes  2 
Canu 
Pilon 
Snippy 
SPAdes 
Prokka 
IDBA-UD 
ABRicate​B 
mlst​B 
ESOM 
BLAST 
Kraken 
Fresh  
122 Yes Illumina MiSeq 0.0002 Liver  
Chronic 
hepatic 
brucelloma  
Yes  1 
Mothur  
Kraken 
BWA 
Frozen  
123 Yes  
Illumina 
HiSeq 2000 
and 2500 
1 Broncho-alveolar lavage 
Chronic 
pneumonia Yes 1 
CLARK 
Kraken 
MetaPhlAn2 
USEARCH 
UBLAST 
Frozen 
124 Yes  Illumina HiSeq  X 
Cerebrospinal 
Fluid 
Meningitis 
and 
encephalitis 
No  204 
MAFFT 
PhyML 
SURPI+ 
Frozen  
125 Yes  Nanopore MinION N/A 
Sputum, 
bronchoalveo
lar lavage 
(BAL) and 
endotracheal 
aspirates 
(ETAs) 
Lower 
respiratory 
infections 
Yes​I  40 
Porechop 
Minimap2 
Canu 
BLAST 
WIMP 
ARMA 
Frozen  
126 No  
Illumina 
HiSeq 
2500 
1.85 Resected prostheses 
Prosthetic 
joint 
infections  
Yes  N/A 
MetaPhlAn2 
BioBloom  
BWA 
BBMap  
Fresh 
 
Leveraging the potential of metagenomics approaches for therapeutic applications of 
microbial research 
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The microbiome has a strong effect on an individual’s ability to interact with, excrete, or 
metabolize food and medication. Understanding the impact that the microbiome has on the 
activity of pharmaceutical drugs will become essential for clinicians to develop personalized 
therapies for patients. Understanding the link between an individual’s microbiome and 
metabolism, weight gain, and metabolic diseases can also be used in personalized medicine. 
Specifically, metagenomics-based approaches show promise in predicting an individual’s 
probability of developing melanoma and IBD, as well as determining the amount of a medication 
that will actually be processed in a patients’ body (bioavailability). Metagenomics has a clear 
role in potential development of microbiome-based treatment -- including treating individuals 
with unhealthy gut microbiota, obesity, and diabetes. Protocols for this precision metagenomics 
have already been proposed​127​. 
 
Microbes (such as those in the phylum Bacteroidetes) have even been shown to interfere with the 
liver’s decomposition of widely used drugs, such as acetaminophen, leading to the increased 
formation of more toxic and carcinogenic compounds​6​. Additionally, a decrease in Bacteroidetes 
abundance has been seen in women who have indicators of blood glucose control issues​128–130​. 
Aside from modulating drug activity, the most important potential applications can be found in 
the administration of cancer treatments. The presence of certain microbes can increase or 
decrease the toxicity or efficacy of treatment​7​. Having an outline of the microbes present inside a 
patient can inform doctors on the appropriate course of drugs. 
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There are additional applications of microbiome-based treatment (including treating individuals 
having unhealthy gut microbiota) and the role of metagenomics in developing such applications 
is a topic of current study. These studies have led to the trial use of microbiome transplants as a 
treatment plan for various infections and conditions and have the potential to replace standard 
antibacterial treatments ​that are quickly becoming ineffective​44,131–133​.​ Fecal Microbiota 
Transplants (FMT) have emerged as a viable treatment for ​Clostridioides difficile ​infection 
(CDI). As CDI increases in prevalence​134–137​, the risk for recurrent infection is also escalating, 
with a 20-60% chance of experiencing a CDI again​138,139​. CDI drastically decreases the fecal 
bacterial diversity in an affected person, and FMT is considered an effective treatment in adults, 
although the adverse effects are not well known or characterized. Recently, the death of a patient 
caused the FDA to issue a safety alert regarding the transfer of multidrug-resistant organisms by 
FMT​140​, which reinforces the importance of screening the donor prior to administering a FMT to 
the patient. Metagenomic methods facilitated an in depth investigation of the longitudinal 
changes on children’s gut microbiome pre- and post-FMT and the potential acquisition of 
antimicrobial resistant genes (AMR) and pathogens from their adult donors​141​. In this study, 
FMT reduced AMR genes and potential pathogens within the children, and the microbial 
diversity increased post-FMT and was sustained over time​141​. Because of the resolution that 
shotgun metagenomics provides, bacterial species that are in high abundance in the human gut​142 
were shown to increase significantly post-FMT; this difference, along with other changes in 
abundances of species, was not detected when using 16S rRNA sequencing​143​. The efficacy of 
this treatment strategy for more complex microbiota-associated gastrointestinal disorders 
remains to be tested but trials are currently ongoing to test the application of FMT in IBD, IBS, 
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and obesity​144​. Additionally, FMT has also been considered as a treatment for neuropsychiatric 
disorders, such as autism in which patients treated with FMT experienced improved 
symptoms​144,145​. As with CDI, the functional capability that was changed post-FMT​141​ can also be 
investigated with these other, more complex disorders with the use of metagenomics .  
 
Connections between the human microbiome and various metabolic functions have been the 
topic of study for a number of years. In a recent study using ​Akkermansia muciniphila ​as a 
supplement for three months, patients saw an increase in insulin sensitivity, and a slight decrease 
in body weight (−2.27 ± 0.92 kg, P = 0.091) compared to the control (which took a placebo)​146​. 
 
Discussion 
 
Metagenomic methods have a wide range of utility and applications. These include, but are not 
limited to, infection detection, surveillance and tracking of outbreaks, antimicrobial resistance 
prediction and strain resolution, and disease prognosis. 
 
Overcoming the current limitations of metagenomics methods is necessary not only for the field 
of microbiology to progress, but also to overcome the major hurdle of acquiring clinical 
validation. The method must be reproducible, reliable, and accurate to be clinically applicable​147​ , 
which most metagenomic tools are not. As of writing this paper, there are only three validated 
clinical tools based on metagenomics methods. The first is the use of cerebrospinal fluid to 
identify the infectious agent in encephalitis and meningitis cases. This is done by the Clinical 
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Microbiology Lab at UC San Francisco. The second is the use of bronchoalveolar lavage fluid 
for lower respiratory tract infections. This is done by IDbyDNA. Finally, identification of 
microbial cell-free DNA from blood plasma is done by Karius Inc. All of these methods 
underwent extreme scrutiny and have published papers providing evidence that their method is 
reproducible, reliable, and accurate​148–150​. 
 
Clinical validation also depends on financial interest in the medical research and development 
community. Insurance companies traditionally have not covered the costs of metagenomic tests 
for individuals who wish to use available novel methods. This is because there is not yet enough 
data showing that these methods can effectively improve patient outcomes. There need to be 
larger studies and pilot programs that can demonstrate that not only are these methods effective, 
but that are capable of saving lives and money while also reducing the need to depend on general 
antibiotics both as a health issue and as antimicrobial resistance continues. 
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 Supplementary Materials 
Table S1. Supplementary Note 1. ​Comparison of available sequencing platforms. ​Platform​ is 
the sequencing machine referenced. ​Company​ is the current producer of the sequencing platform. 
Error rate​ is the percentage of the base pairs that are incorrectly read during sequencing. ​Average 
read length​ is the average length, in base pairs, of the reads generated by the sequencing platform 
when fed DNA. ​Bases per run​ is the throughput, in gigabases, that the machine can output every 
time it process a sample of DNA. ​Time spent per run​ is the amount of time the sequencer takes to 
process a sample of DNA. ​Cost per Gb​ is the amount of money, in US currency, to produce one 
Gigabyte of sequencing data. ​Release year​ is the year the sequencing platform was released for 
scientific use. Average read length, Bases per run, and release year were pulled from 
‘Developments in high throughput sequencing’​21​. For ABI Sanger, Error Rate and Cost per Gb 
was acquired from a paper entitled ‘Comparison of Next-Generation Sequencing Systems’​151 
Platform Company Error 
Rate 
Average 
Read 
Length 
(bp) 
Bases per 
run 
(gigabases
) 
Time 
spent per 
run (hrs) 
Cost per 
Gb  
(US 
Dollars) 
Release 
Year 
ABI 
Sanger 
3730xl 
Applied 
Biosystems 
.001 800 0.0000768 0.5-2.5  
$5,000,000 
2002 
IonTorren Ion Torrent ~1% 400 2 7.3 $460 2013 
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t PGM 
Illumina 
MiSeq 
Solexa, 
Illumina 
0.2% 300 15 21-56 $110 2013 
Illumina 
HiSeq 
2500 
Solexa, 
Illumina 
0.2% 250 300 ~40 $45 2014 
PacBio 
RSII 
Pacific 
Biosciences 
~13
% 
13,500 12 
 
2 $600 2013 
Nanopore 
MinION 
Oxford 
Nanopore 
32% 9545 42 ~0-50 $750 2015 
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